STOCK MARKET BSE NSE

More delay in Covid vaccine 'Sputnik V' roll-out in Delhi-NCR

Fortis Healthcare, which had said that it would make Sputnik V available at its Gurgaon and Mohali hospitals, has also not started administering the Russian vaccine to people so far.

Published: 27th June 2021 01:29 PM  |   Last Updated: 27th June 2021 01:29 PM   |  A+A-

Sputnik V vaccine. (Photo | PTI)

By PTI

NEW DELHI: The roll-out of Russian COVID-19 vaccine 'Sputnik V' at various private hospitals in the Delhi-NCR region has been delayed again, officials said on Sunday.

"We do not have a clarity on the dates of the vaccine roll-out," a spokesman of Apollo Hospitals said.

Indraprastha Apollo here had earlier said that it would tentatively start administering the two-dose vaccine by June 25.

An official of Madhukar Rainbow Children's Hospital said the facility has also not received Sputnik V doses so far from Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country.

"There is a delay on the part of the suppliers. They have not shared any specific reason for it. I think it could be related to the supply of both the doses together," he said.

Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans.

The two doses, given 21 days apart, are different and not interchangeable.

Fortis Healthcare, which had said that it would make Sputnik V available at its Gurgaon and Mohali hospitals, has also not started administering the Russian vaccine to people so far.

The Centre has fixed the price of the vaccine at Rs 1,145 per dose.

The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at RS 780 per dose, while that of Covaxin at Rs 1,410 per dose.

Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed the vaccine and the Russian Direct Investment Fund (RDIF) is marketing it globally.

Dr Reddy's Laboratories has been importing the shots from Russia.

Over a period of time, the vaccine is also going to be manufactured in India.

According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp